Abeona Therapeutics Inc.

Abeona Therapeutics Inc.verified

ABEO

Price:

$5.98

Market Cap:

$259.96M

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biophar...[Read more]

Industry

Biotechnology

IPO Date

1980-09-19

Stock Exchange

NASDAQ

Ticker

ABEO

The PE Ratio as of November 2024 (TTM) for Abeona Therapeutics Inc. (ABEO) is -2.92

According to Abeona Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.92. This represents a change of 2.58% compared to the average of -0.11 of the last 4 quarters.

Abeona Therapeutics Inc. (ABEO) Historical PE Ratio (quarterly & annually)

How has ABEO PE Ratio performed in the past?

The mean historical PE Ratio of Abeona Therapeutics Inc. over the last ten years is -5.13. The current -2.92 PE Ratio has changed 5.60% with respect to the historical average. Over the past ten years (40 quarters), ABEO's PE Ratio was at its highest in in the June 2024 quarter at 5.67. The PE Ratio was at its lowest in in the September 2017 quarter at -32.21.

Quarterly (TTM)
Annual

Average

-5.13

Median

-2.06

Minimum

-24.16

Maximum

-0.25

Abeona Therapeutics Inc. (ABEO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Abeona Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 2.45%

Maximum Annual PE Ratio = -0.25

Minimum Annual Increase = -117.65%

Minimum Annual PE Ratio = -24.16

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.98159.68%
2022-0.76101.52%
2021-0.38-77.06%
2020-1.65-23.31%
2019-2.15-64.14%
2018-5.99-75.21%
2017-24.16218.74%
2016-7.5818.73%
2015-6.382.45%
2014-0.25-117.65%

Abeona Therapeutics Inc. (ABEO) Average PE Ratio

How has ABEO PE Ratio performed in the past?

The current PE Ratio of Abeona Therapeutics Inc. (ABEO) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.04

5-year avg

-1.38

10-year avg

-5.13

Abeona Therapeutics Inc. (ABEO) PE Ratio vs. Peers

How is ABEO’s PE Ratio compared to its peers?

Abeona Therapeutics Inc.’s PE Ratio is less than Reviva Pharmaceuticals Holdings, Inc. (-1.19), less than Athira Pharma, Inc. (-0.23), less than Fortress Biotech, Inc. (-0.62), less than ACADIA Pharmaceuticals Inc. (21.14), less than Cabaletta Bio, Inc. (-0.88), less than Calithera Biosciences, Inc. (0), less than Affimed N.V. (-0.00), less than Checkpoint Therapeutics, Inc. (-0.54), greater than Adaptimmune Therapeutics plc (-3.48), greater than Mereo BioPharma Group plc (-3.77), greater than Pieris Pharmaceuticals, Inc. (-13.56), less than PDS Biotechnology Corporation (-1.39), less than Leap Therapeutics, Inc. (-1.90), less than X4 Pharmaceuticals, Inc. (-1.63), greater than Terns Pharmaceuticals, Inc. (-4.05), greater than Day One Biopharmaceuticals, Inc. (-5.12), greater than Inozyme Pharma, Inc. (-15.73), less than REGENXBIO Inc. (-1.84), less than Anebulo Pharmaceuticals, Inc. (-2.04), greater than Invivyd, Inc. (-4.78), less than Black Diamond Therapeutics, Inc. (-0.37), less than null (-1.96),

Build a custom stock screener for Abeona Therapeutics Inc. (ABEO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Abeona Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Abeona Therapeutics Inc. (ABEO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Abeona Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Abeona Therapeutics Inc.'s PE Ratio?

How is the PE Ratio calculated for Abeona Therapeutics Inc. (ABEO)?

What is the highest PE Ratio for Abeona Therapeutics Inc. (ABEO)?

What is the 3-year average PE Ratio for Abeona Therapeutics Inc. (ABEO)?

What is the 5-year average PE Ratio for Abeona Therapeutics Inc. (ABEO)?

How does the current PE Ratio for Abeona Therapeutics Inc. (ABEO) compare to its historical average?